Teresa Macarulla
Sobre mi
La Dra. Teresa Macarulla és cap del Servei d’Oncologia Mèdica de l’Hospital Clínic de Barcelona. Especialitzada en tumors hepatobiliopancreàtics, lidera assaigs clínics de fases I–III en teràpies dirigides. El seu treball ha contribuït a aprovacions de l’FDA i l’EMA i a publicacions d’alt impacte. Dirigeix un equip multidisciplinari que integra recerca clínica i translacional per avançar en estratègies personalitzades per a càncers gastrointestinals alts
Publicacions destacades
-
Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRASG12C inhibitors.
Autors:Referència: Annals Of Oncology 2025. -
A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRIFOX.
Autors:Referència: American Journal Of Clinical Oncology-Cancer Clinical Trials 2025. -
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
Autors:Referència: Journal Of Clinical Oncology 2025. -
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial
Autors:Referència: Journal Of Clinical Oncology 2025. -
Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial
Autors:Referència: Esmo Open 2025. -
Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy
Autors:Referència: Clinical Cancer Research 2024. -
Facts and Hopes in the Systemic Therapy of Biliary Tract Carcinomas
Autors:Referència: Clinical Cancer Research 2024. -
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Autors:Referència: Clinical Cancer Research 2021.
